Mirtazapina Mylan Generics Italia (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Mylan Generics Italia, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients. It is marketed throughout the European Union and is available by prescription only.

GNH USA supplies Mirtazapina Mylan Generics Italia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance across EU and global markets.

Mirtazapina Mylan Generics Italia is a NaSSA antidepressant used in the management of depressive disorders.

- Major depressive disorder: alleviates depressive symptoms and improves mood in adult patients. - Treatment‑resistant depression: may be added when first‑line antidepressants have insufficient effect. - Depressive episodes with insomnia: helps improve sleep quality while treating depressive symptoms.

Mirtazapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis or other severe blood dyscrasias - Hepatic dysfunction or jaundice - Seizures - Suicidal thoughts or behavior, especially early in treatment - Severe hypotension - Allergic reactions such as rash or angioedema

Before initiating therapy, clinicians should consider several safety aspects.

- Assess hepatic function: adjust use in patients with liver impairment. - Monitor weight and appetite: significant gain may occur. - Caution in cardiovascular disease: watch for orthostatic hypotension. - Avoid abrupt discontinuation: taper to reduce withdrawal symptoms. - Use cautiously in the elderly: increased risk of sedation and falls. - Store at ambient temperature: keep in the original pack, protect from moisture.

Mirtazapine can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma levels. - Other CNS depressants (e.g., benzodiazepines, opioids): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - SSRIs or SNRIs: potential for serotonin syndrome. - Antihypertensive agents: possible enhanced hypotensive effect. - Alcohol: increased sedation and impairment.